FAM83A, originally identified as BJ-TSA-9, is overexpressed in lung cancer and breast cancer tumors, and it is associated with breast cancer refractoriness to EGFR-TKI (tyrosine kinase inhibitors) (14, 23). Here, EGFR is linked to breast carcinoma.